Boston Scientific Corporation $BSX Shares Sold by Keybank National Association OH

Keybank National Association OH trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 35.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 24,005 shares of the medical equipment provider’s stock after selling 13,356 shares during the quarter. Keybank National Association OH’s holdings in Boston Scientific were worth $1,048,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BSX. BlackRock Inc. acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific during the 2nd quarter worth $2,156,233,000. Jupiter Topco LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth $803,357,000. Janus Henderson Group PLC grew its holdings in shares of Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after acquiring an additional 3,907,981 shares during the last quarter. Finally, Amundi raised its position in shares of Boston Scientific by 1.2% during the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after purchasing an additional 173,208 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Robert W. Baird upped their target price on Boston Scientific from $50.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Mizuho set a $50.00 price objective on Boston Scientific in a report on Thursday, October 29th. Piper Sandler reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Finally, Citigroup cut their price target on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Check Out Our Latest Analysis on BSX

Boston Scientific Price Performance

Shares of BSX opened at $44.33 on Monday. The business’s 50-day moving average is $44.00 and its 200-day moving average is $54.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. The company has a market capitalization of $64.25 billion, a price-to-earnings ratio of 18.78, a P/E/G ratio of 1.31 and a beta of 0.60. Boston Scientific Corporation has a fifty-two week low of $39.57 and a fifty-two week high of $104.61.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the company posted $0.75 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

Boston Scientific Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Recommended Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.